Skip to main content

Trial Milestone: CX.5 SHAPE randomizes 600 patients

600 PATIENTS RANDOMIZED!!!

Congratulations to Dr. Willibald Schroeder and the team at GYNAEKOLOGICUM Bremen, Germany for enrolling the 600th patient to the SHAPE study! On behalf of the SHAPE trial committee, we would like to thank you for your tremendous and unwavering support of our trial. The countdown is on....let's see the SHAPE trial reach its accrual goal by the end of 2019!

About the trial

A Randomized Phase III Trial Comparing Radical Hysterectomy and Pelvic Node Dissection vs Simple Hysterectomy and Pelvic Node Dissection in Patients with Low-Risk Early Stage Cervical Cancer. (SHAPE)

The reason this study is being done is to see if a simple hysterectomy is as good as a radical hysterectomy in preventing cancer of the cervix from returning, and whether, because less tissue surrounding the uterus is removed during surgery, there are fewer side-effects after the surgery and in the long-term.

Eligibility: Histologically confirmed adenocarcinoma, squamous, or adenosquamous cancer of the cervix. Diagnosis has been made by LEEP, cone or cervical biopsy and has been reviewed and confirmed by the local reference gynecological pathologist.